Scientist works to reduce side effects of radiation therapy

April 18, 2005

WINSTON-SALEM, N.C. - A Wake Forest University Baptist Medical Center researcher has received a $1.5 million grant to study whether the same drugs that fight obesity and diabetes may be able to also prevent a common side effect of cancer treatment - the cognitive problems that can follow whole-brain radiation.

"Radiation is an effective treatment, but 20 to 40 percent of patients who get whole-brain radiation develop cognitive impairment within a year," said Mike Robbins, Ph.D., professor of radiation biology. "Their families and friends notice that they aren't as sharp as they used to be. The impairment is chronic and progressive."

These cognitive problems can include difficulty with concentration, language, memory and abstract reasoning.

With funding from the National Cancer Institute, Robbins will test whether drugs designed to block certain receptors in the brain can help prevent brain injury from radiation. About 175,000 cancer patients each year receive radiation treatments that target the whole brain or large areas of the brain.

Currently, there are no known treatments to prevent cognitive impairment that can result from the treatment. Robbins said that the aging American population makes it imperative to solve the problem.

"Cancer is a disease of old age, so the number of people getting whole-brain radiation will increase," he said.

Robbins says that, in essence, radiation speeds up the brain's aging process. Researchers believe the cause may be chronic inflammation or oxidative stress, which occurs when cells cannot remove free radicals, or structurally unstable cells that can damage healthy cells.

Robbins' project is based on new evidence that some of the same drugs used to treat obesity and diabetes may also prevent inflammation. In laboratory studies, he will explore the use of drugs that block peroxisome proliferator-activated receptors (PPARs). These receptors are known to control fat and glucose metabolism, and new evidence suggests they are also involved in inflammation.

Drugs already on the market are designed to treat obesity and diabetes by blocking the receptors. Robbins believes that the same drugs may be able to prevent or reduce the severity of cognitive impairment after whole-brain radiation.

"The drugs are available and we know the doses that patients can safely take," said Robbins. "If our theory is successful in the laboratory, this could easily be applied to patients. We know the drugs don't promote tumor growth, and in some cases may inhibit it."

This is one of several research projects looking for way to reduce the side effects of whole brain radiation. Robbins is also evaluating a blood pressure medication and a drug used to treat Alzheimer's disease as potential treatments for patients undergoing radiation. He has worked for more than 20 years on the effects of radiation in normal tissue.

Robbins' project is part of $4.5 million in research grants recently awarded to the Brain Tumor Center of Excellence. The goal of the center, which was formed in 2004, is to find better treatments - and one day a cure - for malignant brain tumors. In addition to its focus on research, the center provides a comprehensive program for patient care, and is the first center in the state to offer Gamma Knife stereotactic radiosurgery, a knifeless approach to brain surgery and radiation therapy.
-end-
Media Contacts: Karen Richardson, krchrdsn@wfubmc.edu; Shannon Koontz, shkoontz@wfubmc.edu; at 336-716-4587

About Wake Forest University Baptist Medical Center: Wake Forest Baptist is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university's School of Medicine. The system comprises 1,282 acute care, psychiatric, rehabilitation and long-term care beds and is consistently ranked as one of "America's Best Hospitals" by U.S. News & World Report.

Wake Forest Baptist Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.